XG 102
XG-102, a TAT-coupled dextrogyre peptide inhibiting the c-Jun N-terminal kinase, was shown efficient in the treatment of experimental uveitis. Research show that XG-102 peptide has potential for treating intraocular inflammation.
Online Inquiry
| CAT# | 10-101-141 |
| CAS | 1198367-70-2 |
| Synonyms/Alias | AM 111;XG 102 peptide;D-JNKI-1 |
| M.F/Formula | C164H285N65O41 |
| M.W/Mr. | 3823.49 |
| Sequence | H-D-Asp-D-Gln-D-Ser-D-Arg-D-Pro-D-Val-D-Gln-D-Pro-D-Phe-D-Leu-D-Asn-D-Leu-D-Thr-D-Thr-D-Pro-D-Arg-D-Lys-D-Pro-D-Arg-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-Gly-OH |
| Labeling Target | c-Jun N-terminal kinase (JNK) |
| Activity | Inhibitor |
| Biological Activity | XG-102, a TAT-coupled dextrogyre peptide inhibiting the c-Jun N-terminal kinase, was shown efficient in the treatment of experimental uveitis. |
| Areas of Interest | Inflammation |
| Target | JNK |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
